Business, Company, Lenses, Local, News, Products

Fresh six-year MiYOSMART data unveiled at ARVO

New six-year data on Hoya Vision Care’s defocus myopia spectacle lens presented at ARVO 2022 has answered key questions over rebounding effects and the lens’ ability to sustain its myopia controlling effect over time.

The findings of the longest study on a myopia management spectacle lens were shared by Professor Carly Lam from the Centre for Myopia Research at The Hong Kong Polytechnic University who conducted the research.

The results of the six-year clinical study conducted on 90 children in Asia looked at the progression of myopia in children who wore the Hoya’s MiYOSMART spectacle lens with with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology.

The results build an original two-year, double-blind randomised trial1, published in the British Journal of Ophthalmology, that concluded children aged 8-13 years wearing MiYOSMART had 60% less myopia progression compared with single-vision wearers as measured by the axial elongation, and a 59% reduction in spherical equivalent refraction.

Subsequent three-year data2 showed the lens continued to slow myopia progression, while patients who switched from single-vision to MiYOSMART had a significant slowdown in their condition.

According to Hoya, the findings of the six-year, long-term follow-up study proved the MiYOSMART spectacle lens myopia control effect is sustained over time for children wearing the lens.

It also confirmed that patients who stop wearing the MiYOSMART spectacle lens show no rebound effects when compared to the initial myopia rates of progression during the two-year randomised control trial or with the general population.

“This six-year follow-up clinical study on the MiYOSMART spectacle lens, the longest study conducted on a myopia management spectacle lens ever, shows the myopia control effects are sustainable over time which is very exciting news,” said Ms Natalia Vlasak, global head of medical and scientific affairs at Hoya Vision Care.

“This study also answered another key question from eye care professionals which was about the rebound effect of the lens – we are very pleased that this clinical study proves that there is no rebound effect if lens use is stopped.”

Launched in 2018, the MiYOSMART spectacle lens was developed in cooperation with The Hong Kong Polytechnic University to address myopia.

Since 2018, one million patients in more than 30 countries have benefited from wearing the MiYOSMART spectacle lens. The lens was launched in Australia in October 2020.

References

  1. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739
  2. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664

More reading

Covering all bases of myopia management

Hoya launches Oliver Wolfe Junior frames

Hoya launches defocus myopia lens for children

© All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

JOIN OUR NEWSLETTER

JOIN OUR NEWSLETTER
Close